These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25384989)

  • 1. Discontinued drugs in 2012 - 2013: hepatitis C virus infection.
    Gentile I; Buonomo AR; Zappulo E; Borgia G
    Expert Opin Investig Drugs; 2015 Feb; 24(2):239-51. PubMed ID: 25384989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinued cardiovascular drugs in 2013 and 2014.
    Zhao HP; Xiang BR
    Expert Opin Investig Drugs; 2015; 24(8):1083-92. PubMed ID: 26162717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.
    Gentile I; Coppola N; Buonomo AR; Zappulo E; Borgia G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1211-23. PubMed ID: 24848437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and development of small molecule HCV antivirals.
    Ni ZJ; Wagman AS
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):446-59. PubMed ID: 15338954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinued cardiovascular drugs in 2015.
    Zhao HP; Dai Y; Xiang BR
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1093-101. PubMed ID: 27427204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
    Klibanov OM; Williams SH; Smith LS; Olin JL; Vickery SB
    Pharmacotherapy; 2011 Oct; 31(10):951-74. PubMed ID: 21950642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG; Chen KX; Shih NY; Piwinski JJ
    Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus.
    Gentile I; Zappulo E; Buonomo AR; Borgia G
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):775-82. PubMed ID: 24840817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C.
    Shah N; Pierce T; Kowdley KV
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection.
    Flanagan S; Crawford-Jones A; Orkin C
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):691-704. PubMed ID: 25209158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.
    Takaya D; Yamashita A; Kamijo K; Gomi J; Ito M; Maekawa S; Enomoto N; Sakamoto N; Watanabe Y; Arai R; Umeyama H; Honma T; Matsumoto T; Yokoyama S
    Bioorg Med Chem; 2011 Nov; 19(22):6892-905. PubMed ID: 21992802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucosidase inhibitors as antiviral agents for hepatitis B and C.
    Durantel D; Alotte C; Zoulim F
    Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclatasvir for the treatment of hepatitis C virus infection.
    Adler H; Lambert JS
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):725-38. PubMed ID: 24882552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future therapies for hepatitis C virus infection: from viral proteins to host targets.
    Imran M; Manzoor S; Khattak NM; Khalid M; Ahmed QL; Parvaiz F; Tariq M; Ashraf J; Ashraf W; Azam S; Ashraf M
    Arch Virol; 2014 May; 159(5):831-46. PubMed ID: 23979177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapies for hepatitis C: insights from the structure of the virus.
    Fusco DN; Chung RT
    Annu Rev Med; 2012; 63():373-87. PubMed ID: 21942423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: investigational agents for chronic hepatitis C.
    Thompson AJ; McHutchison JG
    Aliment Pharmacol Ther; 2009 Apr; 29(7):689-705. PubMed ID: 19183149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.